Business and Capital Alliance with 木村情報技術株式会社
First written in FY2019. 2 of 3 entries say "Restated". Latest entry: FY2020-Q2.
No other company in this theme has enough history to compare yet.
- FY2020-Q2RestatedAnnual report
「・Capital and business alliance with 木村情報技術株式会社, which possesses ICT technologies including AI. The company is strengthening its business standardisation business and pursuing synergies in the medical and pharmaceutical markets. In particular, it is promoting the integration and expansion of online products in response to the impact of the novel coronavirus.」
The company continues its capital and business alliance with 木村情報技術株式会社 and is pursuing the integration and expansion of online products, in addition to synergies in business standardisation and the medical and pharmaceutical markets. - FY2020-Q1RestatedAnnual report
「・Entered into a capital and business alliance with 木村情報技術株式会社, which possesses ICT technologies including AI. The companies will strengthen the business standardization business and develop synergies in the healthcare and pharmaceutical markets.」
The company reaffirmed its capital and business alliance with 木村情報技術株式会社 as a strategic M&A transaction under its medium-term management plan and is pursuing synergies by strengthening the business standardisation business and expanding into the medical and pharmaceutical markets. - FY2019First statedAnnual report
「At a meeting of the Board of Directors held on 27 November 2019, the company resolved to enter into business and capital alliance agreements with 木村情報技術株式会社 and to dispose of treasury shares through a third-party allotment to that company, in order to acquire its shares through an in-kind contribution involving the disposal of the company's treasury shares. The business and capital alliance agreements were signed on the same date.」
The alliance is intended to use ICT technologies in the business standardisation business, utilise and analyse data converted into information assets, and generate synergies in the manufacturing, mobility, medical and pharmaceutical industries. It involves the disposal of 122,900 treasury shares with a total value of ¥300 million.